As mentioned above, tumor samples, PDXs, and cell lines from Group 3 displayed an inter‐tumoral heterogeneity regarding the level of pathway activation, some of them showing a very strong P‐Smad2 basal level. This evidence concerns the gene SMAD2 and neoplasm.